Isoherranen N, Lutz J, Chung S, Hachad H, Levy R, Ragueneau-Majlessi I
Chem Res Toxicol. 2012; 25(11):2285-300.
PMID: 22823924
PMC: 3502654.
DOI: 10.1021/tx300192g.
Harder S, Thurmann P
Clin Pharmacokinet. 1996; 30(6):416-44.
PMID: 8792056
DOI: 10.2165/00003088-199630060-00002.
Feely J, Collins W, Cullen M, el Debani A, MacWalter R, Peden N
Br J Clin Pharmacol. 1993; 35(3):321-3.
PMID: 8471413
PMC: 1381585.
DOI: 10.1111/j.1365-2125.1993.tb05702.x.
Kirch W, Hoensch H, Janisch H
Clin Pharmacokinet. 1984; 9(6):493-510.
PMID: 6096071
DOI: 10.2165/00003088-198409060-00002.
Thijssen H, Janssen G, Baars L
Eur J Clin Pharmacol. 1986; 30(5):619-23.
PMID: 3758150
DOI: 10.1007/BF00542424.
A long lasting gastrin response to apomorphine revealed by inhibitors of gastric acid secretion.
Goiny M, Brodin K, ELWIN C, Uvnas-Moberg K
Naunyn Schmiedebergs Arch Pharmacol. 1987; 336(1):20-4.
PMID: 3627288
DOI: 10.1007/BF00177746.
Comparative effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of warfarin in man.
Toon S, Hopkins K, Garstang F, Rowland M
Eur J Clin Pharmacol. 1987; 32(2):165-72.
PMID: 3582481
DOI: 10.1007/BF00542190.
Cimetidine and ranitidine on basal and ACTH-stimulated steroidogenesis.
Karlstadt R, Frank W, Antell L, Shapowal S, Palmer R
Gut. 1987; 28(12):1688-91.
PMID: 3428700
PMC: 1433917.
DOI: 10.1136/gut.28.12.1688.
Pharmacokinetic interactions of cimetidine 1987.
Somogyi A, Muirhead M
Clin Pharmacokinet. 1987; 12(5):321-66.
PMID: 3301148
DOI: 10.2165/00003088-198712050-00002.
Lack of efficacy of cimetidine and ranitidine as inhibitors of tolbutamide metabolism.
Adebayo G, Coker H
Eur J Clin Pharmacol. 1988; 34(6):653-6.
PMID: 3169118
DOI: 10.1007/BF00615234.
Ranitidine versus cimetidine. A comparison of their potential to cause clinically important drug interactions.
Smith S, Kendall M
Clin Pharmacokinet. 1988; 15(1):44-56.
PMID: 3042245
DOI: 10.2165/00003088-198815010-00004.
Haematological adverse effects of histamine H2-receptor antagonists.
Aymard J, Aymard B, Netter P, Bannwarth B, Trechot P, Streiff F
Med Toxicol Adverse Drug Exp. 1988; 3(6):430-48.
PMID: 2905759
DOI: 10.1007/BF03259895.
Adverse reactions and interactions with H2-receptor antagonists.
Penston J, Wormsley K
Med Toxicol. 1986; 1(3):192-216.
PMID: 2878343
DOI: 10.1007/BF03259837.
Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome.
Clissold S
Drugs. 1986; 32(3):197-221.
PMID: 2875864
DOI: 10.2165/00003495-198632030-00001.
Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.
Grant S, Langtry H, Brogden R
Drugs. 1989; 37(6):801-70.
PMID: 2667937
DOI: 10.2165/00003495-198937060-00003.
A comparison of the influence of famotidine and cimetidine on phenytoin elimination and hepatic blood flow.
Sambol N, Upton R, CHREMOS A, Lin E, Williams R
Br J Clin Pharmacol. 1989; 27(1):83-7.
PMID: 2565119
PMC: 1379708.
DOI: 10.1111/j.1365-2125.1989.tb05338.x.
Effect of cimetidine and ranitidine on the hepatic and renal elimination of nicotine in humans.
Bendayan R, Sullivan J, Shaw C, Frecker R, Sellers E
Eur J Clin Pharmacol. 1990; 38(2):165-9.
PMID: 2338114
DOI: 10.1007/BF00265978.
Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).
Lauritsen K, Laursen L, Rask-Madsen J
Clin Pharmacokinet. 1990; 19(2):94-125.
PMID: 2199130
DOI: 10.2165/00003088-199019020-00002.
Side effects of ranitidine.
Vial T, Goubier C, Bergeret A, Cabrera F, EVREUX J, Descotes J
Drug Saf. 1991; 6(2):94-117.
PMID: 2043287
DOI: 10.2165/00002018-199106020-00002.
Interaction of tertatolol with rifampicin and ranitidine pharmacokinetics and antihypertensive activity.
Kirch W, Milferstadt S, Halabi A, Rocher I, Efthymiopoulos C, Jung L
Cardiovasc Drugs Ther. 1990; 4(2):487-91.
PMID: 1981019
DOI: 10.1007/BF01857758.